Long-term results encouraging for combination immunotherapy for advanced melanoma

The first long-term follow-up results from a phase 1b immunotherapy trial combining drugs for advanced melanoma patients has shown encouraging results -- long-lasting with high survival rates -- researchers report. The trial evaluated the safety and activity of the combination regimen of nivolumab (anti-PD-1), an investigational PD-1 immune checkpoint inhibitor, and ipilimumab (anti-CTLA-4; Yervoy), given either concurrently or sequentially, to patients with advanced melanoma whose disease progressed after prior treatment.

Read the whole article on Science Daily

More from Science Daily